

CLASSIFIEDS

BUSINESS

BUSINESS OFFERS

We are Filmayan India LLP. Are You Searching for a Media Partner to empower your Startup? Contact us:- +91-9029090050 www.filmayanindia.com Mail:- info@filmayanindia.com 0050175548-1

IMPORTANT
 Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

NEOGEN CHEMICALS LIMITED													
Regd. Office: Office No. 1002, 10 th Floor, Dev Corpora Bldg, Opp. Cadbury Co, Pokhran Road No. 2, Khopat, Thane - 400601 CIN: L24200MH1989PLC050919; Tel No.: +91 22 2549 7300; Email: investor@neogenchem.com; Website: www.neogenchem.com													
Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2020 (₹ in Lakhs)													
SR. NO.	PARTICULARS	STANDALONE						CONSOLIDATED					
		For the Quarter Ended			For the Nine months ended			For the Quarter Ended			For the Nine months ended		For the Year Ended
		31 Dec 2020 Unaudited	30 Sept 2020 Unaudited	31 Dec 2019 Unaudited	31 Dec 2020 Unaudited	31 Dec 2019 Unaudited	31 Mar 2020 Audited	31 Dec 2020 Unaudited	30 Sept 2020 Unaudited	31 Dec 2019 Unaudited	31 Dec 2020 Unaudited	31 Dec 2019 Unaudited	31 Mar 2020 Audited
I	Total Income from operations (net)	8,532.15	8,217.75	8,239.50	24,424.86	22,407.92	30,644.88	8,521.33	8,198.44	8,231.32	24,383.62	22,391.54	30,622.09
II	Total Expenses	7,335.62	7,188.86	7,086.43	21,318.84	19,412.90	26,523.61	7,335.62	7,188.86	7,086.43	21,318.84	19,412.90	26,523.62
III	Profit/(loss) before taxes (I-II)	1,196.53	1,028.89	1,153.07	3,106.02	2,995.02	4,121.27	1,194.18	1,026.10	1,150.52	3,097.94	2,986.76	4,109.68
IV	Income Tax												
	1. Current Tax	293.50	229.00	297.50	703.50	777.50	1,148.50	293.50	229.00	297.50	703.50	777.50	1,148.50
	2. Deferred Tax	49.45	59.22	33.84	193.59	74.30	95.53	49.45	59.22	33.84	193.59	74.30	95.53
V	Profit for the period (III-IV)	853.58	740.67	821.73	2,208.93	2,143.23	2,877.24	851.23	737.88	819.18	2,200.85	2,134.96	2,865.55
VI	Total Other comprehensive (expense)/income, net of tax	2.31	(0.77)	(12.11)	6.94	(36.45)	(52.59)	2.31	(0.77)	(12.11)	6.94	(36.45)	(52.59)
VII	Total comprehensive income for the period (V+VI)	855.89	739.90	809.62	2,215.87	2,106.77	2,824.65	853.55	737.11	807.07	2,207.79	2,098.51	2,813.06
VIII	Paid up equity Share Capital (Face Value per share of ₹ 10/- each)	2,333.46	2,333.46	2,333.46	2,333.46	2,333.46	2,333.46	2,333.46	2,333.46	2,333.46	2,333.46	2,333.46	2,333.46
IX	Earnings Per Share ₹												
	Basic & Diluted *Not Annualised	3.67*	3.17*	3.46*	9.50*	9.03*	12.33	3.66*	3.16*	3.46*	9.46*	9.03*	12.28

Notes:

- The above unaudited financial results of the Company for the quarter and nine months ended December 31, 2020 have been prepared in accordance with the IND AS as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 and were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2021.
- In order to continue and to maintain the operations during lock down, various changes in employee transport, additional incentives for employees and contract workers, insurance benefits were provided by the company. The future impact of Covid-19 on the operations and financials of the Company depends on future developments that are uncertain and unpredictable. The company is continuously monitoring the economic conditions and has outlined certain measures to combat the pandemic situation and to minimize the impact on its business.
- Previous period/year's figures have been regrouped/rearranged wherever necessary to make them comparable.
- The company is in the business of manufacturing of specialty chemicals and accordingly has one reportable business segment
- For more details on results, visit investor relations section of the Company's website at www.neogenchem.com and financial result under corporates section of Stock Exchange's website at www.nseindia.com and www.bseindia.com.

Place: Thane, India
 Date : 13th February, 2021

For and on behalf of Board of Directors
HARIDAS KANANI
 Chairman and Managing Director
 DIN: 00185487



Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026.
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099.
Tel No.: +91-22-4018 9999 **Fax No.:** +91-22-4018 9986
Email: complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com
CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2020

(₹ In Millions)

Particulars [Refer notes below]	Standalone						Consolidated					
	Quarter ended 31/12/2020 (Unaudited)	Quarter ended 30/09/2020 (Unaudited)	Quarter ended 31/12/2019 (Unaudited)	Nine months ended 31/12/2020 (Unaudited)	Nine months ended 31/12/2019 (Unaudited)	Year ended 31/03/2020 (Audited)	Quarter ended 31/12/2020 (Unaudited)	Quarter ended 30/09/2020 (Unaudited)	Quarter ended 31/12/2019 (Unaudited)	Nine months ended 31/12/2020 (Unaudited)	Nine months ended 31/12/2019 (Unaudited)	Year ended 31/03/2020 (Audited)
I Revenue from operations												
(a) Net sales	19,498.23	20,254.92	17,316.48	56,277.60	49,295.04	64,912.00	27,587.36	29,081.18	26,386.20	79,761.37	76,859.55	103,972.28
(b) Other operating income	226.55	366.73	846.37	898.05	1,753.93	2,214.31	280.27	443.61	969.41	1,078.92	1,875.25	2,437.41
Total revenue from operations	19,724.78	20,621.65	18,162.85	57,175.65	51,048.97	67,126.31	27,867.63	29,524.79	27,355.61	80,840.29	78,734.80	106,409.69
II Other income	811.27	634.04	944.91	2,793.80	3,555.00	6,067.88	150.90	(318.81)	329.63	417.23	1,154.57	1,596.02
III Total income (I + II)	20,536.05	21,255.69	19,107.76	59,969.45	54,603.97	73,194.19	28,018.53	29,205.98	27,685.24	81,257.52	79,889.37	108,005.71
IV Expenses												
(a) Cost of materials consumed	6,903.32	7,503.36	6,153.78	20,324.09	17,023.38	22,519.81	7,828.98	8,648.40	6,922.15	23,519.30	19,474.73	25,414.74
(b) Purchases of stock-in-trade	897.98	658.51	921.42	2,319.22	2,816.28	3,652.41	2,532.35	2,976.78	3,111.41	5,726.96	8,486.51	10,290.83
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(197.44)	41.63	(135.20)	(313.05)	(31.19)	487.68	(1,247.66)	(1,218.03)	(770.18)	(1,641.78)	(735.35)	1,280.82
(d) Employee benefits expense	2,806.54	3,375.76	2,641.23	8,554.66	8,299.33	10,723.27	5,966.43	7,002.54	5,572.46	18,065.03	17,305.36	22,547.76
(e) Finance costs	830.41	604.12	595.74	2,033.91	1,928.17	2,563.90	954.07	806.32	960.58	2,697.79	2,788.44	3,773.18
(f) Depreciation, amortisation and impairment expense	412.12	367.94	378.24	1,138.15	1,033.11	1,385.38	1,040.65	1,059.99	1,040.65	3,324.85	2,908.91	4,171.66
(g) Other expenses	4,012.02	4,088.84	4,446.15	10,947.38	11,913.98	16,700.84	7,486.81	6,586.97	8,119.02	19,561.25	21,879.60	29,894.72
Total expenses (IV)	15,664.95	16,640.16	15,001.36	45,004.36	42,983.06	58,033.29	24,672.96	25,843.63	24,975.43	71,253.40	72,108.20	97,373.71
V Profit/(loss) before exceptional items and tax (III - IV)	4,871.10	4,615.53	4,106.40	14,965.09	11,620.91	15,160.90	3,345.57	3,362.35	2,709.81	10,004.12	7,781.17	10,632.00
VI Exceptional items (gain) (Refer note 5)	(459.02)	-	-	(738.92)	-	(185.54)	(134.15)	(31.40)	-	(445.45)	-	(328.76)
VII Profit/(loss) before tax (V - VI)	5,330.12	4,615.53	4,106.40	15,704.01	11,620.91	15,346.44	3,479.72	3,393.75	2,709.81	10,449.57	7,781.17	10,960.76
VIII Tax expense :												
Current tax	932.03	802.53	717.41	2,746.89	2,035.37	2,692.37	1,212.43	1,367.28	1,117.45	3,902.49	3,107.22	3,961.27
Deferred tax	(25.16)	(215.76)	(66.27)	(119.64)	(468.07)	(891.41)	(214.50)	(313.46)	(316.03)	(815.06)	(882.67)	(760.21)
IX Profit/(loss) for the period from continuing operations (VII - VIII)	4,423.25	4,028.76	3,455.26	13,076.76	10,053.61	13,545.48	2,481.79	2,339.93	1,908.39	7,362.14	5,556.62	7,759.70
X Profit/(loss) before tax from discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XI Tax expense of discontinuing operations :												
Current tax	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax	-	-	-	-	-	-	-	-	-	-	-	-
XII Profit/(loss) for the period from discontinuing operations (X - XI)	-	-	-	-	-	-	-	-	-	-	-	-
XIII Profit/(loss) for the period for continuing and discontinuing operations (IX + XII)	4,423.25	4,028.76	3,455.26	13,076.76	10,053.61	13,545.48	2,481.79	2,339.93	1,908.39	7,362.14	5,556.62	7,759.70
XIV Other comprehensive income												
A (i) Items that will not be reclassified to profit or loss	5.11	5.44	(17.06)	16.06	(42.75)	(88.83)	(0.51)	(137.89)	(21.01)	(138.03)	(223.61)	52.52
(ii) Income tax relating to items that will not be reclassified to profit or loss	(1.79)	(1.90)	9.72	(5.62)	18.19	34.61	(0.58)	15.72	9.84	14.76	40.92	15.08
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	1,125.91	(291.15)	353.53	1,094.38	(181.86)	(2,248.33)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	(77.86)	215.22	(39.37)	121.04	(95.88)	(276.42)
XV Total comprehensive income	4,426.57	4,032.30	3,447.92	13,087.20	10,029.05	13,491.26	3,528.75	2,141.83	2,211.38	8,454.29	5,096.19	5,302.55
XVI Total comprehensive income attributable to:												
- Non-controlling interests	-	-	-	-	-	-	0.83	(0.43)	0.95	1.73	1.70	0.03
- Owners of the Company	4,426.57	4,032.30	3,447.92	13,087.20	10,029.05	13,491.26	3,527.92	2,142.26	2,210.43	8,452.56	5,094.49	5,302.52
XVII Other equity	-	-	-	-	-	131,980.47	-	-	-	-	-	60,422.88
XVIII Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)*												
Basic EPS (in Rupees)	15.68	14.28	12.25	46.34	35.63	48.00	8.80	8.29	6.76	26.09	19.69	27.50
Diluted EPS (in Rupees)	15.68	14.28	12.25	46.34	35.63	48.00	8.80	8.29	6.76	26.09	19.69	27.50
XIX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)*												
Basic EPS (in Rupees)	-	-	-	-	-	-	-	-	-	-	-	-
Diluted EPS (in Rupees)	-	-	-	-	-	-	-	-	-	-	-	-
XX Earning per share (EPS) (for continuing and discontinuing operations) (of Re 1/- each) (not annualised)*												
Basic EPS (in Rupees)	15.68	14.28	12.25	46.34	35.63	48.00	8.80	8.29	6.76	26.09	19.69	27.50
Diluted EPS (in Rupees)	15.68	14.28	12.25	46.34	35.63	48.00	8.80	8.29	6.76	26.09	19.69	27.50

* except for the year ended 31 March 2020

- Notes:**
- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
 - The above results were reviewed by the Audit Committee at its meeting held on 11th February, 2021 and approved by the Board of Directors at their meeting held on 12th February, 2021.
 - The results for the quarter and Nine months ended 31st December, 2020 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
 - Pursuant to the Taxation Laws (Amendment) Ordinance 2019 ('Ordinance') issued by Ministry of Law and Justice (Legislative Department) on 20th September 2019 which is effective 1st April 2019, domestic companies have the option to pay corporate Income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Ordinance has subsequently been enacted as Taxation Laws (Amendment) Act, 2019. The Company upon the amendment made an assessment of the impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit and other exemptions. The Company has also re-measured its deferred tax liability following the clarification issued by Technical Implementation Group of Ind AS implementation Committee by applying the lower tax rate in measurement of deferred taxes only to extent that the deferred tax liabilities are expected to be reversed in the period during which it expects to be subject to lower tax rate.
 - Exceptional item:
 Exceptional items in the standalone financial results for the quarter and nine months ended 31st December, 2020 of Rs. 459.02 and Rs. 738.92 respectively and in the consolidated financial results for the quarter and nine months ended 31st December, 2020 of Rs. 134.15 and Rs. 445.45 respectively are on account of gain from transfer of intimate hygiene brand Vwash, Momat brands in certain geographies, sale of IP assets and reimbursement of onetime costs.
 - The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified.
 - The list of subsidiaries as of 31st December, 2020 is provided in Annexure A.
 - The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
 - As at 31st December, 2020, pursuant to Employee Stock Options Scheme 2016, 404,247 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
 - The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Group's financial results for the quarter and Nine months ended 31st December, 2020.
 - Diluted EPS has been computed considering the effect of conversion of ESOPs.
 - Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited
Annexure A
List of entities included in the consolidated financial results for quarter and nine months ended 31 December 2020

1 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2 Glenmark Pharmaceuticals Europe Ltd., U.K. 3 Glenmark Pharmaceuticals S.R.O. 4 Glenmark Pharmaceuticals SK, S.R.O. 5 Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.A.) 6 Glenmark Holding S.A. 7 Glenmark Pharmaceuticals S.R.L (liquidated with effect from 30 July 2020) 8 Glenmark Pharmaceuticals SP z.o.o. 9 Glenmark Pharmaceuticals Inc. 10 Glenmark Farmaceut

रमेश पतंगे हे समरसतेचे सारथी - सुरेश हावरे

सरसंघचालक मोहन भागवत यांच्या हस्ते उद्या मुंबईत सत्कार

मुंबई : साप्ताहिक विवेकचे माजी संपादक, हिंदुस्थान प्रकाशन संस्थेचे अध्यक्ष आणि सामाजिक समरसता चळवळीचे अग्रणी रमेश पतंगे यांचा अमृत महोत्सव सोमवार, १५ फेब्रुवारी रोजी रवींद्र नाट्य मंदिर प्रभादेवी येथे सायंकाळी सहा वाजता साजरा होणार आहे. यानिमित्ताने रा. स्व. संघाचे सरसंघचालक मोहन भागवत यांच्या हस्ते त्यांचा सत्कार होईल. तसेच रमेश पतंगे यांच्यावरील गौरव ग्रंथ 'नंदादीप'चे प्रकाशनही या वेळी होईल. समरसता विषय विकसित होत गेला. तो सार्वजनिक झाला, हे पतंगे यांचे श्रेय, असे सामाजिक कार्यकर्ते डॉ. सुरेश हावरे

पतंगे यांच्यामुळेच समरसता विषय राष्ट्रव्यापी

समरसता अध्ययन केंद्र ही रमेश पतंगे आणि मधुभाई कुळकर्णी यांची संकल्पना. ही एक अनोखी अखिल भारतीय संघटना. विभिन्न सामाजिक विषयांचे अध्ययन, संशोधन व अभिसरण ही संस्था करते. याअंतर्गत डॉ. आंबेडकर विमर्श, स्वामी विवेकानंद आणि डॉ. बाबासाहेब आंबेडकर विचारदर्शन, अनुसूचित जाती- सामाजिक वास्तव, भारतीय संविधानाचे अंतरंग अशा अनेक विषयांवर कार्यशाळा-परिसंवाद देशभर झाल्या. पतंगे यांच्यामुळेच समरसता हा विषय आता राष्ट्रव्यापी झाला आणि ते त्या विषयाचे खऱ्या अर्थाने प्रवक्ते झाले आहेत.

यांनी नमूद केले.

या सत्कार समारंभानिमित्त रमेश पतंगे यांचे स्नेही डॉ. सुरेश हावरे म्हणाले, 'मराठवाडा विद्यापीठ

नामांतर, 'रीडस ऑफ राम' इत्यादी विषयांत समरसता मंचाची पर्यायाने रमेश पतंगेची भूमिका मोलाची ठरली. महात्मा फुले, शाहू महाराज,

डॉ. बाबासाहेब आंबेडकर या विषयांवरून कायम संघाला लक्ष्य केले जायचे. असा तो काळ होता. हळूहळू समरसता विषय विकसित होत गेला. तो सार्वजनिक झाला, हे पतंगे यांचे श्रेय, असे हावरे यांनी नमूद केले. नागपूरच्या मोहिते वाड्यावरील शाखेत रमेश पतंगे यांचा बौद्धिक वर्ग झाला. त्या वर्गाला रा. स्व. संघाचे तिसरे सरसंघचालक बाळासाहेब देवस श्रोता म्हणून उपस्थित होते. त्यांनी बौद्धिक वर्ग चांगला झाल्याबद्दल रमेश पतंगे यांचे कौतुक केले होते अशी पतंगे यांची आठवण हावरे यांनी सांगितली.

राज्य सरकारची पालिकेकडे पाच हजार कोटींची थकबाकी

शिक्षण अनुदान, पाणीपट्टी, मालमत्ता कराचा समावेश

लोकसत्ता प्रतिनिधी

मुंबई : मालमत्ता कर, पाणीपट्टी आदी विविध कर-शुल्क तसेच अनुदानापोटी राज्य सरकारने मुंबई महापालिकेचे तब्बल साडेपाच हजार कोटी रुपये थकवले असून त्यात शिक्षणापोटी अनुदान, पाणीपट्टी आणि मालमत्ता कराच्या थकबाकीचा समावेश आहे. शिक्षणाच्या अनुदानापोटी तब्बल साडेतीन हजार कोटी रुपयांच्या थकबाकीचा त्यात समावेश आहे. मुंबई महापालिकेचा राज्यशाकट हाती असलेल्या शिवसेनेचे पक्षप्रमुख उद्धव ठाकरे मुख्यमंत्री आहेत. त्यामुळे राज्य सरकारकडून पालिकेला थकीत रक्कम कधी मिळेल, याकडे सर्वांचे लक्ष लागले आहे.

कोरोना संसर्गांमुळे गेल्या वर्षभरात कर आणि शुल्क वसुली झालेली नाही. त्यामुळे उत्पन्न घसरले आहे. त्याच वेळी कोरोनाविषयक कामांसाठी पालिकेला तब्बल दोन हजार कोटी रुपयांहून अधिकतर रक्कम खर्च करावी लागली आहे.

निधीची गरज...

राज्यात शिवसेना, काँग्रेस आणि राष्ट्रवादी काँग्रेसचे सरकार आहे. तर मुंबई महापालिकेत शिवसेनेची सत्ता आहे.

हाती घेतलेले प्रकल्प, नागरी सोयी-सुविधा, विविध विकासकामे यासाठी पालिकेला मोठ्या निधीची गरज भासणार आहे. पालिकेने आता मालमत्ता कर, पाणीपट्टी न भरणाऱ्या थकबाकीदारांकडे आपला मोर्चा वळविला आहे. ही थकीत रक्कम वसूल करून तिजोरीत आलेली तूट भरून काढण्याचा पालिकेचा मानस आहे.

राज्य सरकारची विविध कार्याये, शासकीय

त्यामुळे पालिकेला थकबाकीची रक्कम मिळावी यासाठी सरकारकडे पाठपुरावा करण्याचा निर्णय पालिकेतील शिवसेना आणि काँग्रेसच्या पदाधिकाऱ्यांनी निर्णय घेतला आहे.

कोरोनामुळे पालिकेच्या आर्थिक स्थितीवर परिणाम झाला आहे. त्यामुळे पालिकेला निधीची गरज आहे. ही हाब लक्षात घेता मुख्यमंत्री थकबाकीची रक्कम पालिकेला देण्याबाबत काय भूमिका घेतात, याकडे सर्वांचे लक्ष लागले आहे.

निवासास्थानांना पालिकेकडून पाणीपुरवठा केला जातो. तसेच या मालमत्तांसाठी मालमत्ता कर भरणे सरकारला बंधनकारक आहे. मात्र सरकारने गेल्या अनेक वर्षांपासून मालमत्ता कर आणि पाणीपट्टीची रक्कम पालिकेच्या तिजोरीत जमा केलेली नाही. तसेच राज्य सरकारकडून पालिकेला साहाय्यक अनुदान दिले जाते. सरकारने पाणीपट्टी, मालमत्ता कर आणि अनुदानापोटी तब्बल पाच हजार २७४ कोटी १६ लाख रुपये थकविले आहेत. मालमत्ता कर व पाणीपट्टीपोटी सुमारे एक हजार ६४५ कोटी रुपये, तर साहाय्यक अनुदानापोटी सुमारे तीन हजार ६२९ कोटी ८३ लाख रुपयांचा थकबाकीमध्ये समावेश आहे. थकबाकीची रक्कम मिळावी यासाठी पालिका प्रशासनाकडून वेळोवेळी पाठपुरावा करण्यात येत आहे. परंतु ही रक्कम अद्याप पालिकेला मिळालेली नाही. उलटपक्षी दरवर्षी थकीत रकमेत वाढ होत आहे.

बृहन्महाराष्ट्र मंडळाचे अधिवेशन कोरोनामुळे लांबणीवर

मुंबई : जगभरातील महाराष्ट्रीयाना एकत्र आणणारे बृहन्महाराष्ट्र मंडळाचे अधिवेशन कोरोना संसर्गांमुळे पुढे ढकलण्यात आले आहे. दर दोन वर्षांनी होणारे हे अधिवेशन २०२१ मध्ये अपेक्षित होते; मात्र गेल्या वर्षी टाळेबंदीमुळे अधिवेशनाचे नियोजन

होऊ शकले नाही. त्यामुळे हे अधिवेशन आता ११ ते १४ ऑगस्ट २०२२ रोजी न्यू जर्सी राज्यातील अटलांटिक सिटीमध्ये होणार आहे. हे विसावे अधिवेशन असेल. नोकरी आणि शिक्षणानिमित्त परदेशात स्थलांतरित आणि नंतर

स्थायिक झालेल्या महाराष्ट्रीय नागरिकांनी विविध देशांमध्ये महाराष्ट्र मंडळे स्थापन केली आहेत. अमेरिका व कॅनडातील सर्व महाराष्ट्र मंडळांना एकत्र आणत परदेशी भूमीत मराठी संस्कृतीचे जतन करणाऱ्या बृहन्महाराष्ट्र मंडळातर्फे दर दोन वर्षांनी

अधिवेशन भरवले जाते. याआधीचे अधिवेशन २०१९ साली झाले होते. मंडळे स्थापन केली आहेत. अमेरिका व कॅनडातील सर्व महाराष्ट्र मंडळांना एकत्र आणत परदेशी भूमीत मराठी संस्कृतीचे जतन करणाऱ्या बृहन्महाराष्ट्र मंडळातर्फे दर दोन वर्षांनी

glenmark
PHARMACEUTICALS LIMITED
Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026.
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099.
Tel No.: +91-22-4018 9999 Fax No.: +91-22-4018 9986
Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com
CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2020

(₹ In Millions)

Particulars (Refer notes below)	Standalone					Consolidated						
	Quarter ended 31/12/2020 (Unaudited)	Quarter ended 30/09/2020 (Unaudited)	Quarter ended 31/12/2019 (Unaudited)	Nine months ended 31/12/2020 (Unaudited)	Nine months ended 31/12/2019 (Unaudited)	Year ended 31/03/2020 (Audited)	Quarter ended 31/12/2020 (Unaudited)	Quarter ended 30/09/2020 (Unaudited)	Quarter ended 31/12/2019 (Unaudited)	Nine months ended 31/12/2020 (Unaudited)	Nine months ended 31/12/2019 (Unaudited)	Year ended 31/03/2020 (Audited)
I Revenue from operations												
(a) Net sales	19,498.23	20,254.92	17,316.48	56,277.60	49,295.04	64,912.00	27,587.36	29,081.18	26,386.20	79,761.37	76,859.55	103,972.28
(b) Other operating income	226.55	366.73	846.37	898.05	1,753.93	2,214.31	280.27	443.61	969.41	1,078.92	1,875.25	2,437.41
Total revenue from operations	19,724.78	20,621.65	18,162.85	57,175.65	51,048.97	67,126.31	27,867.63	29,524.79	27,355.61	80,840.29	78,734.80	106,409.69
II Other income	811.27	634.04	944.91	2,793.80	3,555.00	6,067.88	150.90	(318.81)	329.63	417.23	1,154.57	1,596.02
III Total income (I + II)	20,536.05	21,255.69	19,107.76	59,969.45	54,603.97	73,194.19	28,018.53	29,205.98	27,685.24	81,257.52	79,889.37	108,005.71
IV Expenses												
(a) Cost of materials consumed	6,903.32	7,503.36	6,153.78	20,324.09	17,023.38	22,519.81	7,828.98	8,648.40	6,922.15	23,519.30	19,474.73	25,414.74
(b) Purchases of stock-in-trade	897.98	658.51	921.42	2,319.22	2,816.28	3,652.41	2,532.35	2,976.78	3,111.41	5,726.96	8,486.51	10,290.83
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(197.44)	41.63	(135.20)	(313.05)	(31.19)	487.68	(1,247.66)	(1,218.03)	(770.18)	(1,641.78)	(735.35)	1,280.82
(d) Employee benefits expense	2,806.54	3,375.76	2,641.23	8,554.66	8,299.33	10,723.27	5,966.43	7,002.54	5,572.46	18,065.03	17,305.36	22,547.76
(e) Finance costs	830.41	604.12	595.74	2,033.91	1,928.17	2,563.90	954.07	806.32	960.58	2,697.79	2,788.44	3,773.18
(f) Depreciation, amortisation and impairment expense	412.12	367.94	378.24	1,138.15	1,033.11	1,385.38	1,151.98	1,040.65	1,059.99	3,324.85	2,908.91	4,171.66
(g) Other expenses	4,012.02	4,088.84	4,446.15	10,947.38	11,913.98	16,700.84	7,486.81	6,586.97	8,119.02	19,561.25	21,879.60	29,894.72
Total expenses (IV)	15,664.95	16,640.16	15,001.36	45,004.36	42,983.06	58,033.29	24,672.96	25,843.63	24,975.43	71,253.40	72,108.20	97,373.71
V Profit/(loss) before exceptional items and tax (III - IV)	4,871.10	4,615.53	4,106.40	14,965.09	11,620.91	15,160.90	3,345.57	3,362.35	2,709.81	10,004.12	7,781.17	10,632.00
VI Exceptional items (gain) (Refer note 5)	(459.02)	-	-	(738.92)	-	(185.54)	-	(134.15)	-	(445.45)	-	(328.76)
VII Profit/(loss) before tax (V - VI)	5,330.12	4,615.53	4,106.40	15,704.01	11,620.91	15,345.44	3,479.72	3,393.75	2,709.81	10,449.57	7,781.17	10,960.76
VIII Tax expense :												
Current tax	932.03	802.53	717.41	2,746.89	2,035.37	2,692.37	1,212.43	1,367.28	1,117.45	3,902.49	3,107.22	3,961.27
Deferred tax	(25.16)	(215.76)	(66.27)	(119.64)	(468.07)	(891.41)	(214.50)	(313.46)	(316.03)	(815.06)	(882.67)	(760.21)
IX Profit/(loss) for the period from continuing operations (VII - VIII)	4,423.25	4,028.76	3,455.26	13,076.76	10,053.61	13,545.48	2,481.79	2,339.93	1,908.39	7,362.14	5,556.62	7,759.70
X Profit/(loss) before tax from discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XI Tax expense of discontinuing operations :												
Current tax	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax	-	-	-	-	-	-	-	-	-	-	-	-
XII Profit/(loss) for the period from discontinuing operations (X - XI)	-	-	-	-	-	-	-	-	-	-	-	-
XIII Profit/(loss) for the period from continuing and discontinuing operations (IX + XII)	4,423.25	4,028.76	3,455.26	13,076.76	10,053.61	13,545.48	2,481.79	2,339.93	1,908.39	7,362.14	5,556.62	7,759.70
XIV Other comprehensive income												
A (i) Items that will not be reclassified to profit or loss	5.11	5.44	(17.06)	16.06	(42.75)	(88.83)	(0.51)	(137.89)	(21.01)	(138.03)	(223.61)	52.52
(ii) Income tax relating to items that will not be reclassified to profit or loss	(1.79)	(1.90)	9.72	(5.62)	18.19	34.61	(0.58)	15.72	9.84	14.76	40.92	15.08
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	1,125.91	(291.15)	353.53	1,094.38	(181.86)	(2,248.33)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	(77.86)	215.22	(39.37)	121.04	(95.88)	(276.42)
XV Total comprehensive income	4,426.57	4,032.30	3,447.92	13,087.20	10,029.05	13,491.26	3,528.75	2,141.83	2,211.38	8,454.29	5,096.19	5,302.55
XVI Total comprehensive income attributable to:												
- Non-controlling interests	-	-	-	-	-	-	0.83	(0.43)	0.95	1.73	1.70	0.03
- Owners of the Company	4,426.57	4,032.30	3,447.92	13,087.20	10,029.05	13,491.26	3,527.92	2,142.26	2,210.43	8,452.56	5,094.49	5,302.52
XVII Other equity	-	-	-	-	-	131,980.47	-	-	-	-	-	60,422.88
XVIII Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)*												
Basic EPS (in Rupees)	15.68	14.28	12.25	46.34	35.63	48.00	8.80	8.29	6.76	26.09	19.69	27.50
Diluted EPS (in Rupees)	15.68	14.28	12.25	46.34	35.63	48.00	8.80	8.29	6.76	26.09	19.69	27.50
XIX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)*												
Basic EPS (in Rupees)	-	-	-	-	-	-	-	-	-	-	-	-
Diluted EPS (in Rupees)	-	-	-	-	-	-	-	-	-	-	-	-
XX Earning per share (EPS) (for continuing and discontinuing operations) (of Re 1/- each) (not annualised)*												
Basic EPS (in Rupees)	15.68	14.28	12.25	46.34	35.63	48.00	8.80	8.29	6.76	26.09	19.69	27.50
Diluted EPS (in Rupees)	15.68	14.28	12.25	46.34	35.63	48.00	8.80	8.29	6.76	26.09	19.69	27.50

* except for the year ended 31 March 2020

Notes:

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results were reviewed by the Audit Committee at its meeting held on 11th February, 2021 and approved by the Board of Directors at their meeting held on 12th February, 2021.
- The results for the quarter and Nine months ended 31st December, 2020 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- Pursuant to the Taxation Laws (Amendment) Ordinance 2019 ('Ordinance') Issued by Ministry of Law and Justice (Legislative Department) on 20th September 2019 which is effective 1st April 2019, domestic companies have the option to pay corporate Income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Ordinance has subsequently been enacted as Taxation Laws (Amendment) Act, 2019. The Company upon the amendment made an assessment of the impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit and other exemptions. The Company has also re-measured its deferred tax liability following the clarification issued by Technical Implementation Group of Ind AS implementation Committee by applying the lower tax rate in measurement of deferred taxes only to extent that the deferred tax liabilities are expected to be reversed in the period during which it expects to be subject to lower tax rate.
- Exceptional item:
Exceptional items in the standalone financial results for the quarter and nine months ended 31st December, 2020 of Rs. 459.02 and Rs. 738.92 respectively and in the consolidated financial results for the quarter and nine months ended 31st December, 2020 of Rs. 134.15 and Rs. 445.45 respectively are on account of gain from transfer of intimate hygiene brand Vwash, Momat brands in certain geographies, sale of IP assets and reimbursement of onetime costs.
- The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified.
- The list of subsidiaries as of 31st December, 2020 is provided in Annexure A.
- The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
- As at 31st December, 2020, pursuant to Employee Stock Options Scheme 2016, 404,247 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Group's financial results for the quarter and Nine months ended 31st December, 2020.
- Diluted EPS has been computed considering the effect of conversion of ESOPs.
- Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited

Annexure A

List of entities included in the consolidated financial results for quarter and nine months ended 31 December 2020

1 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2 Glenmark Pharmaceuticals Europe Ltd., U.K. 3 Glenmark Pharmaceuticals S.R.O. 4 Glenmark Pharmaceuticals SK, S.R.O. 5 Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 6 Glenmark Holding S.A. 7 Glenmark Pharmaceuticals S.R.L. (liquidated with effect from 30 July 2020) 8 Glenmark Pharmaceuticals SP z.o.o. 9 Glenmark Pharmaceuticals Inc. 10 Glenmark Therapeutics Inc. 11 Glenmark Farmaceutica Ltda 12 Glenmark Generics S.A 13 Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14 Glenmark Pharmaceuticals Peru SAC 15 Glenmark Pharmaceuticals Colombia SAS, Colombia 16 Glenmark Uruguay S.A. 17 Glenmark Pharmaceuticals Venezuela, C.A 18 Glenmark Dominicana SRL 19 Glenmark Pharmaceuticals Egypt S.A.E. 20 Glenmark Pharmaceuticals FZE 21 Glenmark Impex L.L.C 22 Glenmark Philippines Inc. 23 Glenmark Pharmaceuticals (Nigeria) Ltd 24 Glenmark Pharmaceuticals Malaysia Sdn Bhd 25 Glenmark Pharmaceuticals (Australia) Pty Ltd 26 Glenmark South Africa (pty) Ltd 27 Glenmark Pharmaceuticals South Africa (pty) Ltd 28 Glenmark Pharmaceuticals (Thailand) Co. Ltd 29 Glenmark Pharmaceuticals B.V. 30 Glenmark Arzneimittel GmbH 31 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Kenya Ltd 33 Glenmark Therapeutics AG (liquidated with effect from 2 December 2019) 34 Viso Farmaceutica S.L., Spain 35 Glenmark Specialty SA 36 Glenmark Pharmaceuticals Distribution s.r.o. 37 Glenmark Pharmaceuticals Nordic AB 38 Glenmark Ukraine LLC 39 Glenmark Pharmaceuticals Ecuador S.A. 40 Glenmark Pharmaceuticals Singapore Pte. Ltd. 41 Ichnos Sciences Biotherapeutics SA (Formerly known as Glenmark Biotherapeutics SA) 42 Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) 43 Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited) 44 Glenmark Distribuidora De Medicamentos E Produtos Cosméticos Ltda.

For and on behalf of the Board of Directors

S/d
Glenn Saldanha
Chairman &